Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Efforts are underway to support the development of novel mucosal coronavirus disease 2019 (COVID-19) vaccines. However, there is limited consensus about the complementary role of mucosal immunity in disease progression and how to evaluate immunogenicity of mucosal vaccines. This study investigated the role of oral mucosal antibody responses in viral clearance and COVID-19 symptom duration. METHODS: Participants with polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provided oral fluid for testing with SARS-CoV-2 antibody multiplex assays, nasal swabs for reverse-transcription PCR, and symptom information at up to 8 follow-ups from April 2020 to February 2022. RESULTS: High and moderate oral fluid anti-spike (S) secretory IgA (SIgA) postinfection was associated with significantly faster viral clearance and symptom resolution across age groups with effect sizes equivalent to prior COVID-19 vaccine immunity at the time of infection. Those with high and moderate anti-S SIgA cleared the virus 14 (95% confidence interval [CI], 10-18) days and recovered 9-10 (95% CI, 6-14) days earlier. Delayed and higher anti-S IgG was associated with significantly longer time to clearance and recovery. Experiencing symptoms >4 weeks was associated with lower anti-receptor-binding domain SIgA 15-30 days after infection onset (P < .001). CONCLUSIONS: Robust mucosal SIgA early postinfection appears to support faster clearance of SARS-CoV-2 and recovery from COVID-19 symptoms. This research underscores the importance of harmonizing mucosal immune response assays to evaluate new mucosal vaccines.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution
- Date Crossref
- 12/09/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Centers for Disease Control and Prevention pays non établi dans la noticeOrganisme public
-
Bloomberg School of Public Health Department of Environmental Health and Engineering pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
COVID-19 Response pays non établi dans la noticeInstitution
Johns Hopkins University, Johns Hopkins Medicine et Centers for Disease Control and Prevention, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.